Phaco without limits

Article

Oertli is going to launch its new phaco machine CataRhex 3 on the occasion of this year?s ESCRS in Amsterdam. Never before has such cutting-edge technology been so readily and reliably available for anterior segment surgery, nor has it ever been wrapped in such compact and tempting packaging.

Phaco without Limits - Oertli launches a New Phaco Machine

Oertli is going to launch its new phaco machine CataRhex 3 on the occasion of this year's ESCRS in Amsterdam. Never before has such cutting-edge technology been so readily and reliably available for anterior segment surgery, nor has it ever been wrapped in such compact and tempting packaging.

Weighing only 5 kg, it fits into any pilot case and can be suspended from any IV pole with a simple click. CataRhex 3 is thus the epitome of a portable device. A device that takes up such little space and is so user-friendly is also becoming increasingly attractive to outpatient and high-volume clinics. A trend-setter, CataRhex 3 offers state-of-the-art surgical technologies from clear lens exchange to the hardest lenses in phaco. With HFDS ab interno, it constitutes an elegant MIGS technology in glaucoma surgery.

CataRhex 3 is a power pack incorporating cutting-edge technology. Have a look at the new CataRhex 3 by Oertli and discover the latest breathtaking functions by attending the premiere held at the ESCRS in Amsterdam at booth D06!

Company name: Oertli Instrumente AG
Address: Hafnerwisenstrasse 4, CH-9442 Berneck, Switzerland
Telephone: +41 71 747 42 00
E-mail: info@oertli-instruments.comWebsite: www. oertli-instruments.com or www. oertli-catarhex3.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.